65,437 trials
Tourette Syndrome
Primary: Change From Baseline to Week 6 in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) — -8.8; -7.3; -9.1 Score on scale — p=0.89
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12 — 66.0; 57.5; 31.1 percentage of…
Scabies
Primary: Number of Subjects Who Received a Single Treatment of the Assigned Test Article That Were Designated as "Treatment Success" — 23; 26; 22 Participants — p=0.6084
Gastrointestinal Motility Disorder · Intestinal Disease
Primary: Effect of Lanreotide on Gastrointestinal Motility as Measured by Smart Pill — 371.52; 392; 4767; 5159 minutes — p=0.07
Post Operative Pain Management in Children With Tonsillectomy/Adenoidectomy
Primary: Total Oral Analgesia Consumption — 0.228; 0.224; 0.200; 0.193 cumulative hydrocodone (mg/kg)
GERD
Primary: Association of Change in Patient's GSR From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later — -0.94; -1.70 micro-Siemens — p=0.034
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 24 — 81.0; 80.2; 78.1; 71.4 percentage of…
Disorders of Breast · Breast Lesions
Primary: Percent of Participants With Retrieval of Index Lesion and Magseed — 100 percentage of participants
Head and Neck Cancer · Squamous Cell Carcinoma · Oral Cavity Cancer
Primary: Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided. — 57…
Procedural Sedation · Behavior Disorders
Primary: Number of Patients That Reach a Score Equal or Lower Than 2 Ten Minutes After the Infusion of Dexmedetomidine (Assessed With the PSSS Pediatric Sedation State Scale)…
Pneumococcal Infections
Primary: Percentage of Participants With Solicited Injection-site Adverse Events Following V114 or Prevnar 13™ — 15.1; 14.0; 75.8; 68.8 Percentage of Participants
Solid Tumor
Primary: Number of Patients With Improved Disease Control — 0; 0; 0; 0 Participants
Breast Cancer
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 25; 21; 4; 2 Participants
Breast Neoplasms
Primary: Number of Participants With Screen-Detected Breast Cancer — 95; 87 Participants
Smoking · HIV Infections
Primary: To Determine the Safety of Varenicline in PLWH Who Smoke — 13; 38; 3; 4 Participants